Nectar Lifesciences

What Nectar Lifesciences does

Nectar Lifesciences Limited is a publicly listed Indian pharmaceutical manufacturer (BSE: 532649, NSE: NECLIFE) incorporated in 1995, headquartered in Chandigarh with manufacturing operations in Punjab and Himachal Pradesh. Historically, the company operated three business segments: Active Pharmaceutical Ingredients focused on cephalosporin antibiotics (Cefixime, Cefuroxime Axetil, Ceftriaxone Sodium, Cefotaxime Sodium, Cefpodoxime Proxetil, Cefdinir, Cefepime, and sterile APIs), contract manufacturing of cephalosporin finished dosage forms (tablets, capsules, dry syrups, granules, injectables), and Empty Hard Gelatin Capsules (EHGC) with 4 billion capsule shell annual capacity and unique SMSR (Single Machine Single Room) concept. The company claimed world-leading production capacity in Cefixime Trihydrate, Cefuroxime Axetil, and Cefpodoxime Proxetil, with EUGMP-compliant facilities holding approvals from PMDA Japan, ANVISA Brazil, COFEPRIS Mexico, US FDA, EDQM, and WHO-GMP.

The business operated a B2B enterprise sales model selling directly to global pharmaceutical innovators, generic drug manufacturers, and capsule manufacturers across 45+ countries, with pricing conducted on a quote basis and not publicly disclosed. Manufacturing operations were supported by a 12 MW captive power plant generating 85% of power needs from husk and other feedstocks, and infrastructure spanning 242,000 square meters. The company also operated wholly-owned export subsidiaries (Avensis Exports, Neclife PT Portugal) and ancillary real estate operations.

In November 2025, Nectar Lifesciences divested its API and menthol businesses to Ceph Lifesciences — historically its core revenue-generating segments — and reported zero sales for FY March 2026 with a consolidated net loss of Rs 292.89 crore. Following this divestiture, the company approved a share buyback in December 2025, signaling a strategic pivot toward capital return. Remaining operations include the EHGC business (Nexxicap Minty, Nexxicap Pearl variants), formulations facility at Baddi, and real estate assets. Governance is led by founder Sanjiv Goyal (Chairman & Managing Director since 1995) with a board comprising multiple Independent Directors from Panjab University and a CEO (Amit Chadah), operating with a small headcount of 11-50 employees.

Name

Nectar Lifesciences

Legal name

Nectar Lifesciences Ltd.

Website

https://neclife.com

Company type

Public

Founded year

1995

Operating status

Operating

Headcount range

11–50 employees

Short description

Nectar Lifesciences Limited is an Indian public pharmaceutical manufacturer historically focused on cephalosporin APIs, formulations, and empty gelatin capsules for global pharma companies across 45+ countries, now in operational contraction following the 2025 divestiture of its API and menthol businesses to Ceph Lifesciences.

Ownership category

akta.pro rank

Product category

Cephalosporin API & Formulation Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industries

Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO), Small-Molecule API Process Development & Route Scouting (HLAGAHAA)

Keywords

• Cephalosporin API manufacturing
• Finished dosage formulations
• Empty gelatin capsules
• Contract pharmaceutical manufacturing
• Active pharmaceutical ingredients

Headquarters

HQ city

Chandigarh

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure

Revenue model

1. Active Pharmaceutical Ingredients (APIs): Manufacturing and sale of cephalosporin APIs including Cefixime, Cefuroxime Axetil, Ceftriaxone Sodium, and other antibiotic APIs to pharmaceutical companies globally.
2. Finished Dosage Forms (Formulations): Contract manufacturing of cephalosporin tablets, capsules, dry syrups, dry powder injectables, and granules for global pharma companies.
3. Empty Hard Gelatin Capsules: Manufacturing and sale of empty hard gelatin capsules in various sizes (0, 0el, 1, 2, 3) with customization options for color, printing, and specialized formulations like BSE-free and ethylene oxide-free capsules.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Nectar Lifesciences manufactures and supplies Active Pharmaceutical Ingredients (APIs) — primarily Cephalosporin antibiotics such as Cefixime, Cefuroxime Axetil, Ceftriaxone Sodium, Cefpodoxime Proxetil, and sterile APIs — alongside finished solid dosage formulations (tablets, capsules, dry syrups, injectables) and Empty Hard Gelatin Capsules (EHGC). The company operates EUGMP-compliant manufacturing facilities near Chandigarh and at Baddi, serving global pharmaceutical innovators as a contract manufacturing partner and direct API/capsule supplier.

Product overview

Nectar Lifesciences is a research-driven pharmaceutical manufacturer offering a vertically integrated portfolio of products across three core business segments: Active Pharmaceutical Ingredients (APIs) focused on cephalosporin antibiotics, Formulations for finished dosage forms including contract manufacturing services, and Empty Hard Gelatin Capsules. The company operates manufacturing facilities near Chandigarh in Punjab and Himachal Pradesh, India, with additional formulation capabilities at Baddi. Recent product launches include Nexxicap Minty and Nexxicap Pearl variants in the EHGC segment. The company also maintains real estate operations as part of its diversified business.

Differentiator

Problem solved

Functional benefit

Brands

• Nexxicap Minty: Menthol capsules brand under the Empty Hard Gelatin Capsules product line.
• Nexxicap Pearl

Products and services

• Active Pharmaceutical Ingredients (APIs) - Cephalosporins Manufactured Cephalosporin antibiotic APIs including Cefixime Trihydrate, Cefuroxime Axetil (amorphous and crystalline), Cefotaxime Sodium, Ceftriaxone Sodium, Cefpodoxime Proxetil, Cefprozil, Cefdinir, Cefuroxime Sodium, Cefazolin Sodium, Ceftazidime pentahydrate and Cefepime + Arginine, supplied to global pharmaceutical companies for use in antibiotic medications. The company claims world-leading production capacity for Cefixime Trihydrate, Cefuroxime Axetil, Cefpodoxime Proxetil and Sterile APIs. Note: the API business was disposed of to Ceph Lifesciences on 2025-11-25.
• Formulations - Finished Dosage Forms Contract manufacturing services for Cephalosporin solid dosage forms including tablets, capsules, dry powder oral suspension, granules and injectables. Dedicated Cephalosporin facility at Barotiwala (Baddi) Industrial Estate serving global pharmaceutical companies as a contract manufacturing partner.
• Empty Hard Gelatin Capsules (EHGC) Empty hard gelatin capsule shells in sizes 0, 0el, 1, 2 and 3 with customization options for color and printing, available in BSE-free, sulfite-free, sodium-free and ethylene oxide-free formulations. cGMP compliant with US FDA and EDQM norms; among the top 5 EHGC manufacturers in India serving domestic and export markets.
• Nexxicap Minty (Menthol Capsules) Specialized menthol-flavored empty hard gelatin capsule variant within Nectar's EHGC portfolio, formulated for pharmaceutical filling applications.
• Nexxicap Pearl (Pearl Capsules) Specialized pearl-appearance empty hard gelatin capsule variant within Nectar's EHGC portfolio, offering a distinctive aesthetic finish for pharmaceutical filling applications.
• Real Estate Operations Ancillary real estate assets and operations maintained as part of the company's diversified business portfolio alongside its pharmaceutical manufacturing segments.

Quantifiable outcome

• Serving pharmaceutical markets in 45+ countries
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Ceph LifesciencescoreStrategic or Co-development Partner · 25 November 2025Nectar Lifesciences disposed of its API and menthol businesses to Ceph Lifesciences. This represents a significant business restructuring where core business operations were transferred to the partner company. Dr. Surulichamy Senthilkumar, Non Executive Director of Nectar Lifesciences, holds full-time position as Vice President with Ceph Lifesciences Private Limited.

Scale indicators7 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Centrient Pharmaceuticals: Royal DSM/Fresenius-backed Dutch specialty manufacturer of cephalosporin and statin APIs. Directly comparable to Nectar's historical core business of cephalosporin antibiotic API manufacturing at scale for global generics customers.
• Orchid Chemicals and Pharmaceuticals Limited: Indian pharmaceutical company historically focused on cephalosporin APIs and formulations. Direct segment overlap with Nectar's pre-divestiture cephalosporin franchise; one of Nectar's directors (Dr. Senthilkumar) previously worked at Orchid.
• Alembic Pharmaceuticals Limited: Indian vertically integrated manufacturer of APIs (including cephalosporins/antibiotics) and finished formulations for global markets. Comparable in scale, product mix, regulatory positioning, and India-headquartered export-led business model.
• Aarti Drugs Limited: Indian specialty API manufacturer with a strong antibiotic/cephalosporin franchise supplying global generics customers. Similar India-based, B2B export-driven API business model to Nectar's historical operations.
• Hikal Limited: Indian manufacturer of active pharmaceutical ingredients and intermediates across multiple therapeutic categories including anti-infectives. Comparable as a mid-sized India-based API manufacturer with B2B sales to global pharma innovators.
• ACG (Associated Capsules Group): Indian-headquartered manufacturer of empty hard gelatin and HPMC capsules for global pharmaceutical customers. Directly comparable to Nectar's EHGC segment in product category, customer base and regulatory positioning.

Broad incumbents

• Aurobindo Pharma Limited: One of India's largest generic pharmaceutical manufacturers with a sizable cephalosporin API and formulations portfolio. Competes with Nectar across Cephalosporin APIs, finished dosage forms, and export markets in 45+ countries.
• Lupin Limited: India's third-largest pharmaceutical company with cephalosporin formulations and a global commercial footprint. Overlaps with Nectar on cephalosporin finished dosage forms and export markets, but at materially larger scale.
• Sun Pharmaceutical Industries Limited: Largest pharmaceutical company in India with a broad generics, API and specialty portfolio including cephalosporin formulations. Comparable export footprint and regulatory stack but vastly larger scale and diversification.
• Cipla Limited: Indian global pharmaceutical major with API manufacturing, finished formulations and respiratory/infectious disease franchises. Comparable India-headquartered B2B pharma exporter competing in similar tender and institutional markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/nectar-life-science

Compliance25 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nectar Lifesciences